Navigation Links
Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
Date:10/12/2009

SAN FRANCISCO, Oct. 12 /PRNewswire/ -- Takeda San Francisco, Inc. announced today that Michael Buckley, Ph.D., has joined the company as vice president of process sciences. Dr. Buckley will be responsible for directing all aspects of the materials supply to support research and prepare for production of therapeutic antibody candidates at Takeda's antibody IND engine and center of excellence for biologics.

"Mike brings over 20 years of experience in the biopharmaceutical industry and is a great addition to the Takeda San Francisco management team," said Mary Haak-Frendscho, Ph.D., president and chief scientific officer, Takeda San Francisco. "Mike's extensive experience covers all key aspects of antibody drug production, purification, formulation and analytical development. He will play an important role as we expand Takeda's biologics R&D capabilities in order to realize our goals of discovering and advancing superior therapeutics to contribute to the health of individuals."

Dr. Buckley previously has held executive positions with Neugenesis Corporation, Genitope Corporation and Corixa Corporation, leading multi-disciplinary groups in process development, manufacturing and materials management. He also has written multiple IND, BLA and drug master file sections for regulatory submissions. While at Corixa, Dr. Buckley was instrumental in the development of the first centrally manufactured radiopharmaceutical-Iodine-131 antibody (Bexxar(TM)). He holds a Ph.D. in immunology from the UMDNJ Graduate School of Biomedical Sciences, Newark, NJ.

About Takeda San Francisco, Inc.

Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellence and Antibody IND Engine for human antibody therapeutics for the treatment of cancer, inflammation and metabolic diseases. TSF supports Takeda's therapeutic antibody initiative in close collaboration with Takeda's other R&D organizations. Additional information about Takeda San Francisco is available at http://www.takedasf.com.

About Takeda Pharmaceutical Company Limited

Founded in 1781 and located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

SOURCE Takeda San Francisco, Inc.


'/>"/>
SOURCE Takeda San Francisco, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe
2. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
3. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
4. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
5. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
6. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
7. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
8. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
9. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
10. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
11. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... 5, 2017  Just 18 months after its February ... to announce the appointment of three new senior people ... Dominic Jones-Phillips and James Wright ... Tammy Wynne joins ... access writers. She has over ten years, experience in ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... ... to Moorwick”: the adventures of a young Scottish girl yearning to see the world. ... mother of five who used her time waiting for children to finish their extracurricular activities ... It was a way to give some meaning to the hours I waited for ...
(Date:9/20/2017)... ... 2017 , ... “Monique”: is the story of Monique, whose mother’s deteriorating ... published author, Colleen Crispi, has owned four beauty salons and written a book regarding ... estate and cooking. , “The doctor’s office was only three blocks away, and ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading strategy, ... Flannery, to its strategic advisory and client development team. , In her ... clients across different industries to develop and implement market-justified strategies, modernize and transform ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter ... the President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID ...
(Date:9/19/2017)... ... September 19, 2017 , ... CTNext , ... Innovation Awards (EIA), held this past Thursday night at The Space in Hamden. ... presented their innovative project ideas to a panel of judges for an opportunity ...
Breaking Medicine News(10 mins):